Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Allergic rhinitis is a common nasal condition characterized by nasal pruritus, sneezing, rhinorrhea, and nasal congestion. Other symptoms of the condition include, pressure, exaggerated pain responses (hyperalgesia), pain (allodynia), and hyposmia.

The global allergic rhinitis treatment market is estimated to account for US$ 13,950.7 Mn in terms of value and is expected to reach US$ 17,863.6 Mn by the end of 2027.

Global Allergic Rhinitis Treatment Market: Drivers

Increasing prevalence of allergic rhinitis is expected to propel growth of the global allergic rhinitis treatment market over the forecast period. For instance, according to the Centers for Disease Control and Prevention, the U.S. recorded 19.2 million and 5.2 million cases of hay fever in adults aged 18 and over and children under age 18 years, respectively, in 2018.

Moreover, increasing rate of self-medication among patients and availability of over-the-counter (OTC) drugs is also expected to boost demand for allergic rhinitis treatment.

Statistics:

Oral route of administration held dominant position in the global allergic rhinitis treatment market in 2019, accounting for 48.4% share in terms of value, followed by Nasal and Intravenous, respectively.

Figure 1. Global Allergic Rhinitis Treatment Market Share (%), by Value, by Treatment Type, 2019

Allergic Rhinitis Treatment  | Coherent Market Insights

Global Allergic Rhinitis Treatment Market: Restraints

Absence of cure is expected to hinder growth of the global allergic rhinitis treatment market. There is no cure for allergic rhinitis. However, the effects of the condition can be lessened with the use of nasal sprays and antihistamine medications.

Moreover, the symptoms of allergic rhinitis may resemble other conditions or medical problems, which is expected to limit the market growth.

request-sample

Allergic Rhinitis Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 13,450.3 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 3.6% 2027 Value Projection: US$ 17,863.6 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Treatment Type:
    • Immunotherapy: SCIT, SLITD, SLITT.
    • Anti-histamines, Decongestants, Leukotriene Receptor Antagonists, Corticosteroids.
  • By Route of Administration: Oral, Nasal, Intraocular, Intravenous.
  • By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, E-commerce.
Companies covered:

Merck & Co., Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline PLC, Sanofi S.A., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Alcon (Novartis AG), Unichem Laboratories, Mylan, ALK, Innovus Pharmaceuticals, Inc., and Glenmark Pharmaceuticals Ltd

Growth Drivers:
  • Increasing prevalence of allergic rhinitis
  • Number of treatment options
Restraints & Challenges:
  • Absence of disease curing treatment
  • Similarity of symptoms with other diseases

Global Allergic Rhinitis Treatment Market: Opportunities 

High incidence of asthma is expected to offer lucrative growth opportunities for players in the global allergic rhinitis treatment market. For instance, according to The Global Asthma Report 2018, around 300 million people have asthma worldwide, and the number is expected to reach 100 million by 2025.

Moreover, R&D in allergic rhinitis is also expected to aid in growth of the market. For instance, in May 2019, Glenmark Pharmaceuticals announced positive results from a Phase 3 study of Ryaltris, an investigational fixed-dose combination nasal spray for the treatment of seasonal allergic rhinitis.

The global allergic rhinitis treatment market was valued at US$ 13,450.3 Mn in 2019 and is forecast to reach a value of US$ 17,863.6 Mn by 2027 at a CAGR of 3.6% between 2020 and 2027.

Figure 2. Global Allergic Rhinitis Treatment Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

Allergic Rhinitis Treatment  | Coherent Market Insights

Market Trends/Key Takeaways

The market is witnessing R&D of new drugs for improving quality of sleep for allergic rhinitis patients. For instance, in February 2019, ALK released new analysis of clinical trial data showing that its sublingual allergy immunotherapy tablet for the treatment of house dust mite (HDM)-related allergy can significantly improve quality of sleep for allergic rhinitis patients.

Major players in the market are focused on adopting partnership strategies to enhance their market share. For instance, in February 2020, Glenmark Specialty S.A., the Switzerland-based subsidiary of Glenmark Pharmaceuticals Ltd. entered into an exclusive licensing agreement with Hikma Pharmaceuticals PLC for commercializing its novel nasal spray Ryaltris for the treatment of allergic rhinitis in the US.

Global Allergic Rhinitis Treatment Market: Competitive Landscape

Major players operating in the global allergic rhinitis treatment market include, Merck & Co., Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline PLC, Sanofi S.A., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Alcon (Novartis AG), Unichem Laboratories, Mylan, ALK, Innovus Pharmaceuticals, Inc., and Glenmark Pharmaceuticals Ltd.

Global Allergic Rhinitis Treatment Market: Key Developments

Major players in the market are focused on approval and launch of new drugs to expand their product portfolio. For instance, in June 2019, ALK completed the marketing authorization procedure for its tree sublingual allergy immunotherapy tablet ITULAZAX in 17 European countries.

Similarly, in November 2018, Mylan launched Dymista, a new class of treatment for allergic rhinitis in Malaysia.

Allergic rhinitis or hay fever is an IgE-mediated disorder caused by allergens such as mold or tress, animal, dander, house dust mites, weed pollens, and grass. It can occur in two different forms namely, seasonal and perennial, which in turn causes mild or moderate to severe inflammation inside the nose. Some of the major symptoms of allergic rhinitis include nasal congestion, rhinorrhea, sneezing, nasal itching, and itchy eyes, or it can be associated with asthma as well. Allergic rhinitis and sinusitis are linked to each other, as allergic rhinitis blocks the nose, which in turn blocks the sinuses. In 2015, according to World Allergy Organization, over 400 million people suffered from allergic rhinitis worldwide. Moreover, in the U.S., 10-30% adults and around 40% children were affected by allergic rhinitis.

Restraints of the Global Allergic Rhinitis Treatment Market

Major factors hampering the growth of the allergic rhinitis treatment market during the forecast period constitutes of absence of disease curing treatment, and similarity of symptoms with other diseases.

Key features of the study:

  • This report provides in-depth analysis of the global allergic rhinitis treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global allergic rhinitis treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Merck & Co., Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline PLC, Sanofi S.A., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Alcon (Novartis AG), Unichem Laboratories, Mylan, ALK, Innovus Pharmaceuticals, Inc., and Glenmark Pharmaceuticals Ltd.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global allergic rhinitis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Allergic Rhinitis Treatment Market, By Treatment Type:
    • Immunotherapy
      • SCIT
      • SLITD
      • SLITT
    • Anti-histamines
    • Decongestants
    • Leukotriene Receptor Antagonists
    • Corticosteroids
  • Global Allergic Rhinitis Treatment Market, By Route of Administration:
    • Oral
    • Nasal
    • Intraocular
    • Intravenous
  • Global Allergic Rhinitis Treatment Market, By Distribution Channel:
    • Retail Pharmacies
    • Hospital Pharmacies
    • E-commerce
  • Global Allergic Rhinitis Treatment Market, By Geography:
    • North America
      • By Treatment Type
        • Immunotherapy
        • SCIT
        • SLITD
        • SLITT
        • Anti-histamines
        • Decongestants
        • Leukotriene Receptor Antagonists
        • Corticosteroids
      • By Route of Administration
        • Oral
        • Nasal
        • Intraocular
        • Intravenous
      • By Distribution Channel
        • Retail Pharmacies
        • Hospital Pharmacies
        • E-commerce
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Treatment Type
        • Immunotherapy
        • SCIT
        • SLITD
        • SLITT
        • Anti-histamines
        • Decongestants
        • Leukotriene Receptor Antagonists
        • Corticosteroids
      • By Route of Administration
        • Oral
        • Nasal
        • Intraocular
        • Intravenous
      • By Distribution Channel
        • Retail Pharmacies
        • Hospital Pharmacies
        • E-commerce
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Treatment Type
        • Immunotherapy
        • SCIT
        • SLITD
        • SLITT
        • Anti-histamines
        • Decongestants
        • Leukotriene Receptor Antagonists
        • Corticosteroids
      • By Route of Administration
        • Oral
        • Nasal
        • Intraocular
        • Intravenous
      • By Distribution Channel
        • Retail Pharmacies
        • Hospital Pharmacies
        • E-commerce
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Treatment Type
        • Immunotherapy
        • SCIT
        • SLITD
        • SLITT
        • Anti-histamines
        • Decongestants
        • Leukotriene Receptor Antagonists
        • Corticosteroids
      • By Route of Administration
        • Oral
        • Nasal
        • Intraocular
        • Intravenous
      • By Distribution Channel
        • Retail Pharmacies
        • Hospital Pharmacies
        • E-commerce
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Treatment Type
        • Immunotherapy
        • SCIT
        • SLITD
        • SLITT
        • Anti-histamines
        • Decongestants
        • Leukotriene Receptor Antagonists
        • Corticosteroids
      • By Route of Administration
        • Oral
        • Nasal
        • Intraocular
        • Intravenous
      • By Distribution Channel
        • Retail Pharmacies
        • Hospital Pharmacies
        • E-commerce
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Treatment Type
        • Immunotherapy
        • SCIT
        • SLITD
        • SLITT
        • Anti-histamines
        • Decongestants
        • Leukotriene Receptor Antagonists
        • Corticosteroids
      • By Route of Administration
        • Oral
        • Nasal
        • Intraocular
        • Intravenous
      • By Distribution Channel
        • Retail Pharmacies
        • Hospital Pharmacies
        • E-commerce
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Merck & Co., Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Boehringer Ingelheim
    • AstraZeneca Plc
    • GlaxoSmithKline PLC
    • Sanofi S.A.
    • Johnson & Johnson
    • Teva Pharmaceutical Industries Ltd.
    • Alcon (Novartis AG)
    • Unichem Laboratories
    • Mylan
    • Innovus Pharmaceuticals, Inc.
    • Glenmark Pharmaceuticals Ltd.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Treatment Type
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • COVID-19 Impact Analysis
  4. Global Allergic Rhinitis Treatment Market, By Treatment Type, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Immunotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
        • SCIT
        • SLITD
        • SLITT
    • Anti-histamines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Decongestants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Leukotriene Receptor Antagonists
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Corticosteroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
  5. Global Allergic Rhinitis Treatment Market, By Route of Administration, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Nasal
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Intraocular
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Intravenous
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Allergic Rhinitis Treatment Market, By Distribution Channel, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • E-Commerce
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Allergic Rhinitis Treatment Market, By Regions, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Company Profiles
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Boehringer Ingelheim
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • AstraZeneca
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline PLC
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Alcon (Novartis AG)
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Unichem Laboratories
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Mylan Laboratories
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Innovus Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Glenmark Pharmaceuticals Ltd
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 35 market data tables and 26 figures on “Allergic Rhinitis Treatment Market – Global forecast to 2027.

Frequently Asked Questions

The global allergic rhinitis treatment market was valued at US$ 13,450.3 Mn in 2019 and is forecast to reach a value of US$ 17,863.6 Mn by 2027 at a CAGR of 3.6% between 2020 and 2027.
Major factor driving the growth of global allergic rhinitis treatment market during the forecast period include increasing prevalence of allergic rhinitis, and number of treatment options.
Major factors hampering the growth of the allergic rhinitis treatment market during the forecast period constitutes of absence of disease curing treatment, and similarity of symptoms with other diseases.
Oral route of administration held dominant position in the global allergic rhinitis treatment market in 2019.
North America Allergic Rhinitis Treatment market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are Merck & Co., Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline PLC, Sanofi S.A., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Alcon (Novartis AG), Unichem Laboratories, Mylan, ALK, Innovus Pharmaceuticals, Inc., and Glenmark Pharmaceuticals Ltd.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner